Ivabradine HCl , ≥98% , 148849-67-6
                            Synonym(s):
3-[3-[[[(7S)-3,4-Dimethoxybicyclo[4.2.0]octa-1,3,5-trien-7-yl]methyl]methylamino]propyl]-1,3,4,5-tetrahydro-7,8-dimethoxy-2H-3-benzazepin-2-one hydrochloride
                            
                        
                CAS NO.:148849-67-6
Empirical Formula: C27H36N2O5.HCl
Molecular Weight: 505.05
MDL number: MFCD00929899
EINECS: 638-798-3
| Pack Size | Price | Stock | Quantity | 
| 250MG | RMB153.60 | In Stock | 
                                                 | 
                                        
| 1G | RMB494.64 | In Stock | 
                                                 | 
                                        
| 5g | RMB1516.80 | In Stock | 
                                                 | 
                                        
| others | Enquire | 
PRODUCT Properties
| Melting point: | 193-196?C | 
                                    
| alpha | 58921 +7.8°; 36521 +27.8° (c = 1% in DMSO) | 
                                    
| storage temp. | 2-8°C | 
                                    
| solubility | H2O: ≥5mg/mL (warmed) | 
                                    
| form | powder | 
                                    
| color | white to beige | 
                                    
| optical activity | [α]/D +5 to +9°, c = 1 in DMSO | 
                                    
| Water Solubility | H2O: ≥5mg/mL (warmed) | 
                                    
| Merck | 14,5247 | 
                                    
| InChIKey | HLUKNZUABFFNQS-ZMBIFBSDSA-N | 
                                    
| SMILES | C([C@H]1CC2=CC(OC)=C(OC)C=C12)N(C)CCCN1CCC2=CC(OC)=C(OC)C=C2CC1=O.Cl |&1:1,r| | 
                                    
| CAS DataBase Reference | 148849-67-6(CAS DataBase Reference) | 
                                    
Description and Uses
In an effort to develop angina agents without the unwanted negative inotropic and hypotensive effects associated with b-adrenergic blockers and calcium channel blockers, a new class of heart-rate reducing compounds that act specifically on the sinoatrial (SA) node has been explored. These bradycardic agents interact directly with the pacemaking cell of the SA node and the hyperpolarization- activated If , the primary pacemaking current. Ivabradine has evolved as a specific inhibitor of If current through its contact with f-channels on the intracellular side of the plasma membrane. As a consequence, ivabradine reduces the speed of diastolic depolarization and decreases heart rate. It has been approved for the treatment of chronic stable angina and provides a viable alternative to patients with a contraindication or intolerance of b-blockers. Evaluation is also underway for the potential treatment of ischemic heart disease. Using a patch-clamp technique on rabbit sinoatrial node cells, inhibition of If current ranged from 6% (0.03 mM) – 80% (10 mM). .
angina therapeutic



![(1S)-4,5-Dimethoxy-1-[(methylamino)methyl]benzocyclobutanehydrochloride](https://img.chemicalbook.com/CAS/GIF/866783-13-3.gif)



![(Z)-7,8-dimethoxy-1H-benzo[d]azepin-2(3H)-one](https://img.chemicalbook.com/CAS/20180808/GIF/85175-65-1.gif)